Ditchcarbon
  • Contact
  1. Organizations
  2. Vectura
Public Profile
Pharmaceutical Preparation Manufacturing
GB
updated 2 months ago

Vectura Sustainability Profile

Company website

Vectura Group plc, headquartered in Great Britain, is a leading player in the pharmaceutical industry, specialising in the development of inhalation products and drug delivery solutions. Founded in 1997, Vectura has achieved significant milestones, including partnerships with major pharmaceutical companies to enhance respiratory therapies. The company focuses on innovative formulations and device technologies, particularly for asthma and chronic obstructive pulmonary disease (COPD). Vectura's unique approach combines expertise in inhalation science with advanced manufacturing capabilities, positioning it as a trusted partner in the respiratory market. With a strong presence in Europe and North America, Vectura has established itself as a key contributor to improving patient outcomes through its core products and services. Its commitment to research and development continues to drive its success and market leadership in the inhalation therapeutics sector.

DitchCarbon Score

How does Vectura's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

39

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

34

Industry Benchmark

Vectura's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.

58%

Let us know if this data was useful to you

Vectura's reported carbon emissions

In 2023, Vectura reported total carbon emissions of approximately 14,578,000 kg CO2e, with about 13,983,000 kg CO2e attributed to Scope 3 emissions and approximately 595,000 kg CO2e from Scope 1 and 2 combined. This marks a slight increase from 2022, when total emissions were about 14,385,000 kg CO2e, with Scope 3 emissions at approximately 13,981,000 kg CO2e and Scope 1 and 2 emissions at around 404,000 kg CO2e. Vectura's emissions data is cascaded from its parent company, Vectura Group plc, reflecting a corporate family relationship. The company has not set specific reduction targets or initiatives as part of its climate commitments, nor has it engaged with the Science Based Targets initiative (SBTi) for formal reduction targets. Overall, Vectura's emissions profile highlights the significant impact of Scope 3 emissions, which dominate its carbon footprint, indicating a need for comprehensive strategies to address emissions across its value chain.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

20142017201820222023
Scope 1
142,000
0,000,000
0,000,000
-
-
Scope 2
1,272,000
0,000,000
0,000,000
-
-
Scope 3
-
-
-
00,000,000
00,000,000

How Carbon Intensive is Vectura's Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Vectura's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Vectura's Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Vectura is in GB, which has a very low grid carbon intensity relative to other regions.

Vectura's Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Vectura has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Vectura's Emissions with Industry Peers

Novartis Pharmaceuticals UK Limited

GB
•
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

MorphoSys

DE
•
Pharmaceutical Preparation Manufacturing
Updated 13 days ago

Glaxosmithkline

GB
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 1 month ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated 18 days ago

RECORDATI

LU
•
Pharmaceutical Preparation Manufacturing
Updated 19 days ago

Let us know if this data was useful to you

Usage Policy

You're welcome to quote or reference data from this page, but please include a visible link back to this URL.

Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.

See our License Agreement for more details.

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251209.2
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
Available onAWS Marketplace logo
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
Use CaseSBTi-aligned baselining & progress trackingSupplier EngagementClimate-informed sourcing strategyEmission ReportingSustainable Finance
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelogWhitepaper
AboutTeamCareersLicense AgreementPrivacy